OP-Peptide-Linker Antibodies for Nerve Agent Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting organophosphate (OP) nerve agents are inadequate for field use, as they do not prevent neuronal brain damage and incapacitation, and existing treatments are insufficient for acute OP exposure, necessitating a more efficient and fieldable detection and decontamination methodology.
Innovation Solution
Development of compounds such as OP-Peptide-Linker-CP and OP-Peptide-Linker, which utilize peptides derived from OP-modified proteins to generate antibodies for diagnosing OP exposure, allowing for the identification of specific OP agents in biological fluids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional detection methods are used, then detection capability is provided, but the methods are not fieldable and do not prevent neuronal brain damage and incapacitation
Solution Approach 1:
The patent uses peptide mimics that copy the structure and binding properties of actual OP-adducted proteins. These mimics are synthesized peptides containing modified amino acid sequences that replicate the chemical footprint of OP-modified proteins, allowing detection without requiring the actual damaged proteins to be present in the field sample.
Solution Approach 2:
The patent introduces antibody reagents as intermediaries that bind to the peptide mimics. These antibodies serve as detectable proxies that can be introduced into field samples to indirectly detect OP exposure through the peptide-mimic-antibody interaction, enabling detection in resource-limited field settings.
2Object-affected harmful factors
If conventional treatments are used, then some protective effect is achieved, but they do not prevent neuronal brain damage and incapacitation
Solution Approach 1:
The patent enables preliminary detection of OP exposure through the peptide-mimic-antibody system, allowing treatment to be initiated before neuronal damage occurs. By detecting the OP-adduct signature in biological samples, the system provides early warning that enables preventive treatment to avoid the harmful effects of OP poisoning.
3Measurement precision
If antibodies against OP adducts are generated, then specific detection of OP agents is achieved, but the process requires complex immunogen synthesis
Solution Approach 1:
The patent segments the complex OP-adducted protein into simplified peptide mimics containing only the essential amino acid sequences that define the OP binding site. This segmentation reduces the immunogen from entire modified proteins to short peptides (typically 5-20 amino acids), dramatically simplifying synthesis while maintaining specificity.
Solution Approach 2:
The patent focuses the peptide mimics on the local region where OP binding occurs - specifically the amino acid residues that form the active site interaction with OP compounds. By concentrating the immunogen design on this local functional region rather than the entire protein, the system achieves high specificity with minimal synthesis complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds enable timely and accurate detection of OP exposure, facilitating appropriate treatment and reducing long-term health effects by generating specific antibodies for OP-peptides, thereby aiding in the diagnosis of OP adducts in biological samples.
Implementation Method 1
compounds such as OP-Peptide-Linker-CP and OP-Peptide-Linker, which utilize peptides derived from OP-modified proteins to generate antibodies for diagnosing OP exposure
Implementation Method 2
OPs react with AchE or BuChE, forming covalent bonds with these agents through the active site serine
Data Source
AI summary
Provided are methods for identifying OP-adducted biomarkers of OP exposure as well as compounds containing OPs that can provide OP adducts and compounds of Formula 1 for eliciting antibodies that specifically and selectively bind to the OP adducts, wherein the Formula 1 compounds have the structure of OP-Peptide-Linker-CP, wherein CP is a carrier protein, OP represents a structure corresponding to that of a reactive organic phosphorous compound covalently modifying a tyrosine residue hydroxyl group of the peptide of Formula I and the other variable groups are as described herein.